Variations in Oligosaccharide−Protein Interactions in Immunoglobulin G Determine the Site-Specific Glycosylation Profiles and Modulate the Dynamic Motion of the Fc Oligosaccharides
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Glycoproteins, such as immunoglobulin G (IgG), consist of an ensemble of glycosylated variants, or glycoforms, which have different oligosaccharides attached to a common peptide. Alterations in the normal glycoform populations of IgG are associated with certain disease states, notably rheumatoid arthritis and its remission during pregnancy. In this paper, we show that two sets of IgG Fc glycoforms have quite different physical properties. The first set has 1,6 arm terminal galactose residues which interact with the protein, resulting in glycan binding to the protein surface, in agreement with the crystal structure. In contrast, the second set of glycoforms which lack galactose does not bind to the protein surface. Recently developed HPLC techniques combined with enzymatic digestion and mass spectrometry have been used to assign the glycan structures on IgG, Fab, and Fc. Comparison of Fab with Fc shows that glycosylation is site-specific. Two major glycan structures are present on Fab (fucosylated digalacto-bianntenary with and without bisect) and three on Fc (fucosylated agalacto-, 1,6 arm monogalacto-, and digalacto-bianntenary). In comparison to Fab, Fc glycans contain (i) lower levels of bisecting GlcNAc, (ii) lower levels of galactose, (iii) higher than expected levels of 1,6 arm galactose relative to 1,3 arm, and (iv) no 1,6 arm sialylation. We interpret these differences to indicate a role for both the protein quaternary structure and specific protein-glycan interactions in determining the glycoform populations. NMR relaxation measurements have been used to probe the mobility of the glycans in the Fc. By comparing two samples with different glycoform populations, we conclude that this mobility is dependent on the primary sequence of the glycan. Glycans carrying a galactose residue on the 1,6 arm have relaxation properties very similar to those of the peptide backbone and thus do not have independent motion. Glycans lacking galactose have relaxation rates 30 times slower than that of the peptide and thus a higher degree of mobility. These agalactosyl glycans do not interact with the protein, resulting in exposure of previously covered regions of the peptide surface and making the glycan more accessible. This implies that at the early stages of glycan processing the Fc glycans are mobile and only partially protected by the protein quaternary structure. Immobilization of the glycans occurs as a consequence of addition of galactose to the 1,6 arm and results in increased protection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Modified Spin-Echo Method for Measuring Nuclear Relaxation Times
Meiboom, S., & Gill, D. (1958) · Review of Scientific Instruments · doi:10.1063/1.1716296 · Cited by 6,022
A systematic nomenclature for carbohydrate fragmentations in FAB-MS/MS spectra of glycoconjugates
Domon, B., & Costello, C. E. (1988) · Glycoconjugate Journal · doi:10.1007/bf01049915 · Cited by 2,729
The hydrolysis of rabbit γ-globulin and antibodies with crystalline papain
Porter, R. R. (1959) · Biochemical Journal · doi:10.1042/bj0730119 · Cited by 2,308
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Self-citationThe United Kingdom Chemical Database Service
Fletcher, D. A., McMeeking, R. F., & Parkin, D. (1996) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci960015+ · Cited by 1,102
Age-related galactosylation of the N-linked oligosaccharides of human serum IgG.
Parekh, R., Roitt, I., Isenberg, D., Dwek, R., & Rademacher, T. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.5.1731 · Cited by 302
Self-citationParekh, R. B., Tse, A. G., Dwek, R. A., Williams, A. F., & Rademacher, T. W. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02359.x · Cited by 217
Self-citationThe three-dimensional structure of the carbohydrate within the Fc fragment of immunoglobulin G
SUTTON, B. J., & PHILLIPS, D. C. (1983) · Biochemical Society Transactions · doi:10.1042/bst0110130 · Cited by 194
ASHFORD, D., DWEK, R. A., WELPLY, J. K., AMATAYAKUL, S., HOMANS, S. W., LIS, H., TAYLOR, G. N., SHARON, N., & RADEMACHER, T. W. (1987) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1987.tb13516.x · Cited by 152
Self-citationBateman, R. H., Green, M. R., Scott, G., et al. (1995) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.1290091302 · Cited by 73
Research works printed but not linked: 25
- Bole D. G., 1986, J. Cell Biol., 102
- Bordoli R. S., 1994, Rapid Commun. Mass Spectrom. 8, 585−589
- Deisenhofer J., 1981, Biochemistry 20, 2361−2370
- Dwek R. A., 1995, J. Anat., 187
- Furukawa K., 1990, Int. Immunol. 2, 105−112
- Guile G. R., 1996, Anal. Biochem. 240, 210−226
- Harvey D. J., 1994, Org. Mass Spectrom. 29, 753−766
- Harvey D. J., 1995, Rapid Commun. Mass Spectrom. 9, 1556−1561
- Johnson P. M., 1974, Ann. Rheum. Dis. 33, 366−370
- Malhotra R., 1995, (N.Y.) 1, 237−241
- Mizuochi T., 1987, Arch. Biochem. Biophys. 257, 387−394
- Narasimhan S., 1985, Biochemistry 24, 1694−1700
- Newkirk M. M., 1993, J. Rheum., 20
- Nezlin R., 1990, Adv. Immunol., 48, 40
- Parekh R. B., 1987, D. Philos
- Parekh R. B., 1985, Nature 316, 452−457
- Rook G. A. W., 1991, J. Autoimmun., 4
- Rosen P., 1979, Mol. Immunol. 16, 435−436
- Rudd P. M., 1996, J. Biol. Chem. (in press).
- Stanfield R. L., 1990, Science 248, 712−719
- Tsuchiya N., 1989, J. Rheum., 16
- Watkins J., 1970, Clin. Sci. 38, 15p−16p
- Youings A., 1996, J. Biol. Chem., 314
- Young A., 1991, Arthritis Rheum. 34, 1425−1429
- Abbreviations D, one-dimensional
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“Exceptions to the general lack of glycans in crystal structures can occur when the glycan is buried and partially immobilized within the folds of the protein, such as in the case of the Immunoglobulin-G (IgG) Fc-region (504) (505) (506) , or tightly packed on the surface, such as in the HIV virion (507) (508) (509) .”
BackgroundGlycosylation and the Immune System
Rudd, P. M., Elliott, T., Cresswell, P., Wilson, I. A., & Dwek, R. A. (2001) · Science · doi:10.1126/science.291.5512.2370 · Cited by 1,588
Self-citationThe Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins
Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., & Dwek, R. A. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141702 · Cited by 1,307
Self-citationRecapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., & Ravetch, J. V. (2008) · Science · doi:10.1126/science.1154315 · Cited by 849
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Matrix-assisted laser desorption/ionization mass spectrometry of carbohydrates
Harvey, D. J. (1999) · Mass Spectrometry Reviews · doi:10.1002/(sici)1098-2787(1999)18:6<349::aid-mas1>3.0.co;2-h · Cited by 725
Self-citationAnti-Inflammatory Actions of Intravenous Immunoglobulin
Nimmerjahn, F., & Ravetch, J. V. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090232 · Cited by 525
Pučić, M., Knežević, A., Vidič, J., Adamczyk, B., Novokmet, M., Polašek, O., Gornik, O., Šupraha-Goreta, S., Wormald, M. R., Redžić, I., et al. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.010090 · Cited by 524
Self-citationType I and type II Fc receptors regulate innate and adaptive immunity
Pincetic, A., Bournazos, S., DiLillo, D. J., Maamary, J., Wang, T. T., Dahan, R., Fiebiger, B.-M., & Ravetch, J. V. (2014) · Nature Immunology · doi:10.1038/ni.2939 · Cited by 514
Immunoglobulin G glycosylation in aging and diseases
Gudelj, I., Lauc, G., & Pezer, M. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.07.009 · Cited by 408
Mattu, T. S., Pleass, R. J., Willis, A. C., Kilian, M., Wormald, M. R., Lellouch, A. C., Rudd, P. M., Woof, J. M., & Dwek, R. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.4.2260 · Cited by 404
Self-citationControl of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro
Hodoniczky, J., Zheng, Y. Z., & James, D. C. (2005) · Biotechnology Progress · doi:10.1021/bp050228w · Cited by 393
Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding
Houde, D., Peng, Y., Berkowitz, S. A., & Engen, J. R. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900540-mcp200 · Cited by 393
Lauc, G., Huffman, J. E., Pučić, M., Zgaga, L., Adamczyk, B., Mužinić, A., Novokmet, M., Polašek, O., Gornik, O., Krištić, J., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003225 · Cited by 361
Self-citationMimura, Y., Church, S., Ghirlando, R., Ashton, P. R., Dong, S., Goodall, M., Lund, J., & Jefferis, R. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(00)00105-x · Cited by 329
Jefferis, R., Lund, J., & Pound, J. D. (1998) · Immunological Reviews · doi:10.1111/j.1600-065x.1998.tb01188.x · Cited by 329
Modulating IgG effector function by Fc glycan engineering
Li, T., DiLillo, D. J., Bournazos, S., Giddens, J. P., Ravetch, J. V., & Wang, L.-X. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702173114 · Cited by 322
Chemoenzymatic Glycoengineering of Intact IgG Antibodies for Gain of Functions
Huang, W., Giddens, J., Fan, S.-Q., Toonstra, C., & Wang, L.-X. (2012) · Journal of the American Chemical Society · doi:10.1021/ja3051266 · Cited by 308
Evaluation of the serum N ‐linked glycome for the diagnosis of cancer and chronic inflammation
Arnold, J. N., Saldova, R., Hamid, U. M. A., & Rudd, P. M. (2008) · PROTEOMICS · doi:10.1002/pmic.200800163 · Cited by 307
Self-citationFerrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305
Huhn, C., Selman, M. H. J., Ruhaak, L. R., Deelder, A. M., & Wuhrer, M. (2009) · PROTEOMICS · doi:10.1002/pmic.200800715 · Cited by 301
Engineered Antibodies with Increased Activity to Recruit Complement
Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., & Mulkerrin, M. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2571 · Cited by 291
Glycoproteins: glycan presentation and protein-fold stability
Wormald, M. R., & Dwek, R. A. (1999) · Structure · doi:10.1016/s0969-2126(99)80095-1 · Cited by 290
Self-citationGlycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C.-H. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 257
Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity
Nimmerjahn, F., Anthony, R. M., & Ravetch, J. V. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702936104 · Cited by 253
Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIb Binding
Mimura, Y., Sondermann, P., Ghirlando, R., Lund, J., Young, S. P., Goodall, M., & Jefferis, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107478200 · Cited by 236
General mechanism for modulating immunoglobulin effector function
Sondermann, P., Pincetic, A., Maamary, J., Lammens, K., & Ravetch, J. V. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307864110 · Cited by 218
“interactions with the amino acid backbone (23).”
Wilcox, C. R., Holder, B., & Jones, C. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01294 · Cited by 200
“The dynamics and binding affinity of IgG can be influenced by its glycosylation (80) and IgG exists in a number of glycosylated variants (glycoforms) (81).”
BackgroundMetabolic control of recombinant protein N‐glycan processing in NS0 and CHO cells
Baker, K. N., Rendall, M. H., Hills, A. E., Hoare, M., Freedman, R. B., & James, D. C. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.1051 · Cited by 184
Reusch, D., Haberger, M., Maier, B., Maier, M., Kloseck, R., Zimmermann, B., Hook, M., Szabo, Z., Tep, S., Wegstein, J., et al. (2015) · mAbs · doi:10.4161/19420862.2014.986000 · Cited by 168
“The peak assignment of the monogalactosylated species was deduced from literature data: the peaks with upper (α1,6)-arm galactosylation were found for all methods to elute prior to the peaks with lower (α1,3)-arm galactosylation.(61-66) .”
Jimenez del Val, I., Nagy, J. M., & Kontoravdi, C. (2011) · Biotechnology Progress · doi:10.1002/btpr.688 · Cited by 135
“The close proximity of both Cc2 domains in IgG molecules limits the space available for the oligosaccharide structures, thus limiting their branching and complexity.(13)”
BackgroundChung, S., Quarmby, V., Gao, X., Ying, Y., Lin, L., Reed, C., Fong, C., Lau, W., Qiu, Z. J., Shen, A., et al. (2012) · mAbs · doi:10.4161/mabs.19941 · Cited by 127
“Specifically, the N-glycans stabilize particular conformations of the CH2 domains and act as spacers, holding the CH 2 domains apart to provide an open state of the horseshoe-shaped IgG-Fc fragment, allowing increased accessibility and tighter binding to Fcγ receptors.(7,16-18) The majority of human IgG-Fc N-linked gl…”
BackgroundMetabolic control of recombinant monoclonal antibody N‐glycosylation in GS‐NS0 cells
Hills, A. E., Patel, A., Boyd, P., & James, D. C. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.10022 · Cited by 127
Glycosylation and Fc Receptors
Hayes, J. M., Cosgrave, E. F. J., Struwe, W. B., Wormald, M., Davey, G. P., Jefferis, R., & Rudd, P. M. (2014) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-319-07911-0_8 · Cited by 110
Self-citationProduction of α2,6-sialylated IgG1 in CHO cells
Raymond, C., Robotham, A., Spearman, M., Butler, M., Kelly, J., & Durocher, Y. (2015) · mAbs · doi:10.1080/19420862.2015.1029215 · Cited by 106
Antibody glycoengineering strategies in mammalian cells
Wang, Q., Chung, C., Chough, S., & Betenbaugh, M. J. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26567 · Cited by 95
Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies
Yu, X., Baruah, K., Harvey, D. J., Vasiljevic, S., Alonzi, D. S., Song, B.-D., Higgins, M. K., Bowden, T. A., Scanlan, C. N., & Crispin, M. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4014375 · Cited by 84
Self-citationPotential deleterious role of anti‐Neu5Gc antibodies in xenotransplantation
Salama, A., Evanno, G., Harb, J., & Soulillou, J. (2015) · Xenotransplantation · doi:10.1111/xen.12142 · Cited by 81
The Possible Role of Anti-Neu5Gc as an Obstacle in Xenotransplantation
Tector, A. J., Mosser, M., Tector, M., & Bach, J.-M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00622 · Cited by 60
Jayo, R. G., Thaysen-Andersen, M., Lindenburg, P. W., Haselberg, R., Hankemeier, T., Ramautar, R., & Chen, D. D. Y. (2014) · Analytical Chemistry · doi:10.1021/ac5010212 · Cited by 54
Impact of Fc N-glycan sialylation on IgG structure
Zhang, Z., Shah, B., & Richardson, J. (2019) · mAbs · doi:10.1080/19420862.2019.1655377 · Cited by 46
Production of Highly Sialylated Monoclonal Antibodies
Raymond, C., Robotham, A., Kelly, J., Lattova, E., Perreault, H., & Durocher, Y. (2012) · Glycosylation · doi:10.5772/51301 · Cited by 20
“It has been suggested that the galactose on the α1,6 arm may limit further elongation by maintaining the branch close to the CH2 protein surface [8].”
Background
Metadata
- Authors
- Wormald, M. R., Rudd, P. M., Harvey, D. J., Chang, S.-C., Scragg, I. G., & Dwek, R. A.
- Affiliations
- University of Oxford (GB)
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1997-02-01
- Volume
- 36
- Issue
- 6
- Pages
- 1370-1380
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W1986262138
- Cited by
- 191
- References
- 14
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 2 · 2022: 4 · 2021: 6 · 2020: 8 · 2019: 8 · 2018: 5 · 2017: 10 · 2016: 8 · 2015: 9 · 2014: 12 · 2013: 12 · 2012: 10
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Engineering and Physical Sciences Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- IgG, Fc glycosylation, site-specific glycosylation, glycoforms, NMR relaxation, bisecting GlcNAc, fucosylated glycans
- MeSH terms
- Carbohydrate Sequence, Chromatography, High Pressure Liquid, Glycosylation, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Kinetics, Models, Molecular, Molecular Sequence Data, Oligosaccharides, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.